Norgine welcomes TGA registration in Australia of IFINWIL® for adults and children diagnosed with high-risk neuroblastoma [1]

Norgine United Kingdom United States of America France Germany Spain Australia

IFINWIL®: now TGA registered in AustraliaChildren diagnosed with neuroblastoma are on average just 2 years old2The average survival rate of children with HRNB is only 50%2View original content:https://www.prnewswire.com/news-releases/norgine-welcomes-tga-registration-in-australia-of-ifinwil-eflornithine-for-adults-and-children-diagnosed-with-high-risk-neuroblastoma-hrnb1-302430893.html